Coya Therapeutics (COYA) Other Non-Current Assets (2021 - 2026)
Coya Therapeutics (COYA) posted Other Non-Current Assets of $1.1 million for Q4 2022, up 1181.58% sequentially from $87181.0 in Q4 2021, and up 1181.58% YoY from $87181.0 in Q4 2021.
Coya Therapeutics (COYA) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Coya Therapeutics has reported Other Non-Current Assets for 2 years, with the latest figure at $1.1 million in Q4 2022.
- Quarterly Other Non-Current Assets rose 1181.58% year-over-year to $1.1 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.1 million (up 1181.58% YoY) and the FY2022 annual result came in at $1.1 million, up 1181.58% from the prior year.
- Other Non-Current Assets climbed to $1.1 million in Q4 2022 per COYA's latest filing, from $87181.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.1 million in Q4 2022 and troughed at $87181.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | 244,727.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 244,727.00 |
| Dec 31, 2022 | 1.12 Mn |
| Dec 31, 2021 | 87,181.00 |